Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DV 601

Drug Profile

DV 601

Alternative Names: DV-601; HBV therapy - Dynavax; Therapeutic hepatitis B vaccine (DV-601) - Dynavax; Theravax programme - Dynavax

Latest Information Update: 27 Aug 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rhein Biotech
  • Developer Dynavax Technologies
  • Class Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 16 Oct 2013 No development reported - Phase-I for Hepatitis B (combination therapy) in Poland (Parenteral)
  • 16 Oct 2013 No development reported - Phase-I for Hepatitis B in Germany (Parenteral)
  • 29 Dec 2010 DV 601 is still in phase Ib trials for Hepatitis B infection in Poland
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top